Making pharmaceutical healthcare more efficient and sustainable
The programme focuses on the prevention and treatment of disease with medicines, including drugs and vaccines, the effects on quality of life and costs, and the clinical management of drug therapy and drug safety, which all play an important role in healthy ageing.
This research provides more insight into the use and effects of drugs and vaccines, particularly in vulnerable populations, and into how to improve quality of life and promote healthy ageing. The research findings support pharmaceutical decision-making regarding regulatory approval, reimbursement, and optimal medication use in daily practice.
To increase our knowledge and effectively disseminate it, the research team collaborates with local and international networks (e.g. the EU COST Action, MAECON, the H2020 STARS project) and with practice- and policy-oriented organizations (e.g. KNMP, CBG-MEB, LAREB). This strategy has contributed to:
- Drug regulatory decision-making regarding, for instance, the use of real-world data and patient involvement;
- Improvement and implementation of new methods in pharmacovigilance, including use of patient-reported outcomes;
- National practice guidelines, e.g. recommendations for implementing medication deprescribing in elderly patients.